Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Privigen for BK Viremia in Kidney Transplant Recipients
NCT02659891Phase 1Completed
- Sponsor
- Massachusetts General Hospital
- Start
- May 2016
- Primary completion
- Dec 2020
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of polyvalent human immunoglobulin in BK viremia (2 arms), sponsored by Massachusetts General Hospital. Primary endpoint: BK Viremia Clearance at 3 months. Started May 2016; status: completed.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
BK viremia
Beyond the preview
Go deeper on NCT02659891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02659891.